All In Biotech

Drug Trial Radar · NCT04385550

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

A Randomized, Open-label, Controlled, Multicenter Phase III Study of Hydrochloride Capsule Combined With AK105 Injection Versus Standard Second-line Chemotherapy for Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: May 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

528

Planned (sponsor's estimate)

Start

May 20, 2020

Primary completion

Oct 31, 2023

Study completion Dec 31, 2023

Sponsor

Sponsor type
Industry
First posted
May 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.

Conditions

  • Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Interventions

  • Anlotinib hydrochloride capsuleDrug

    Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

  • AK105 injectionDrug

    AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.

  • Paclitaxel injectionDrug

    Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.

  • Docetaxel injectionDrug

    Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: up to 45 weeks

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Shijitan Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • The Sixth Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China

  • Peking University Shougang Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • Quanzhou First Hospital

    Quanzhou, Fujian, China

  • The Second Affiliated Hospital of Fujian Medical University

    Quanzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • AnYang Tumor Hospital

    Anyang, Henan, China

  • Xinxiang Central Hospital

    Xinxiang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Union Hospital,Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nantong Cancer Hospital

    Nantong, Jiangsu, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • Hospital of Jiangnan University

    Wuxi, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Liaoning Cancar Hospital

    Shenyang, Liaoning, China

  • People's Hospital of Ningxia Hui Autonomous Region

    Yinchuan, Ningxia, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.